Stifel analyst Jonathan Block lowered the firm’s price target on ResMed (RMD) to $260 from $270 and keeps a Hold rating on the shares. The stock’s recent pullback is “intriguing,” but if FY27 revenue growth decelerates to a mid-single digit percentage, the current EPS multiple “might be appropriate in the near term,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed downgraded to Neutral from Outperform at Baird
- ResMed receives FDA clearance for PTCS to be marketed as Smart Comfort
- Resmed’s Strategic Positioning and Market Valuation Suggest 19% Upside Despite Future CMS Challenges
- ResMed removed from APAC Conviction List at Goldman Sachs
- ResMed Streamlines Governance at Annual Meeting